Metformin Prescription Rates for Patients with Prediabetes

Journal of the American Board of Family Medicine: JABFM

article

Alejandro Hughes¹  Tamkeen Khan¹  Kate Kirley¹  Tannaz Moin²  Arch Mainous³  Neha Sachdev¹  Janet Williams¹  Gregory Wozniak¹ 

[1] Medical Association;David Geffen School of Medicine at University of California;University of Florida

关键词: Blood Glucose;    Body Mass Index;    Chronic Disease;    Fasting;    Follow-Up Studies;    HbA1c;    Metformin;    Obesity;    Pharmaceutical Preparations;    Population Health;    Prediabetes;    Prescriptions;    Type 2 Diabetes Mellitus;   

DOI  :  10.3122/jabfm.2022.04.210485

学科分类：过敏症与临床免疫学

来源: The American Board of Family Medicine

【 摘 要 】

Purpose: Prediabetes is a serious public health concern, with 34.5% of US adults meeting the criteria for prediabetes. The American Diabetes Association has highlighted metformin therapy as a consideration for individuals with BMI ≥ 35 kg/m2, those aged < 60 years, and women with a history of gestational diabetes. We examined metformin prescription rates among a national sample of commercially insured, higher risk patients with prediabetes.Methods: We gathered 2012 to 2018 demographic, laboratory, and prescription data for 53,551 patients with prediabetes from the IBM MarketScan research database. Our primary outcome was metformin prescription rates 1 or 3 years after a laboratory confirmation of prediabetes among patients who have a BMI ≥ 35 kg/m2 or are aged < 60 years.Results: Overall, 2.4% (n = 1,124) of patients received a metformin prescription within 1 year of a laboratory confirmed prediabetes result, including 2.4% of patients aged < 60 years and 10.4% of those with BMI ≥ 35 kg/m2. By a 3 year follow-up, 4.1% (n = 1901) received a metformin prescription, including 3.9% of patients aged < 60 years and 14.0% with BMI ≥ 35 kg/m2. Patients who developed type 2 diabetes within the 1 (n = 2,769) or 3 year (n = 7,268) follow-up periods were excluded from analysis.Conclusions: Few prediabetes patients who were either obese or aged < 60 years received a metformin prescription between 2012 and 2018. Prescription rates increased slightly between 1 and 3 years after a prediabetes diagnosis, so strategies to support timely intervention among higher risk patients with prediabetes are critically needed.

【 授权许可】

CC BY